Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer (BMS-247550)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00005807 |
Recruitment Status :
Completed
First Posted : January 27, 2003
Last Update Posted : October 9, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or metastatic or unresectable solid tumors.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer Ovarian Cancer Unspecified Adult Solid Tumor, Protocol Specific | Drug: BMS-247550 | Phase 1 |
OBJECTIVES:
- Determine the maximum tolerated dose, recommended phase II dose, and associated toxic effects of BMS-247550 in patients with advanced solid tumors.
- Determine the pharmacokinetic and pharmacodynamic relationship of this treatment regimen in these patients.
- Assess the extent of microtubule bundle and mitotic aster formation and cell cycle kinetics in peripheral blood mononuclear cells in these patients treated with this regimen.
- Determine any evidence of antitumor activity of this treatment regimen in these patients.
- Evaluate the relationship between tumor response and the occurrence of mutation in the class 1 isotype of B-tubulin and B-tubulin isotype distribution in patients with advanced or recurrent solid tumors, ovarian cancer, or breast cancer treated with this regimen.
- Investigate Multi-Drug Resistance Gene (MDR1), Multidrug Resistance-associated Protein (MRP) Gene, and canalicular multispecific organic anion transporter 1(cMOAT) messenger ribonucleic acid (mRNA) and protein expression as prognosticators of tumor response in these patients treated with this regimen.
- Determine the relationship between stathmin expression and phosphorylation status as a function of response in these patients treated with this regimen.
- Correlate the expression of proapoptotic (p53, bax, bad, and bid) and antiapoptotic (survivin, inhibitors of apoptotic proteins, bcl-2, and bcl-x) proteins in tumor samples and/or ascites with response and clinical outcome in these patients treated with this regimen.
OUTLINE: This is a dose-escalation, multicenter study.
- Part I: Patients with advanced solid tumors receive BMS-247550 IV over 1 hour every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Part II: Patients with ovarian, breast, or other cancer receive BMS-247550 as in the part I portion of the study at the MTD. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed at 2 months.
PROJECTED ACCRUAL: Approximately 42-66 patients will be accrued for this study within 12-16 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Scientific Exploratory Study of Epothilone B Analog in Patients With Solid Tumors and Gynecological Malignancies |
Actual Study Start Date : | July 2000 |
Actual Primary Completion Date : | August 2004 |
Actual Study Completion Date : | August 2004 |

Arm | Intervention/treatment |
---|---|
Experimental: Treated Participants
dose escalation treatment
|
Drug: BMS-247550
anticancer agent for the treatment of patients with malignant tumors.
Other Name: epothilone derivative |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 120 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically confirmed metastatic or unresectable solid malignancy for which no standard or curative therapies exist or are no longer effective
- Metastatic, recurrent, or locally advanced breast, ovarian, or other cancer
- Hemoglobin at least 9.0 g/dL
- WBC at least 3,000/mm3
- Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- Bilirubin normal
- AST/ALT no greater than 3 times upper limit of normal
- Gilbert's syndrome allowed
- Creatinine no greater than 2 mg/dL
Exclusion Criteria:
- symptomatic congestive heart failure
- unstable angina pectoris
- cardiac arrhythmia
- grade 2 or greater clinical neuropathy
- prior allergy or hypersensitivity reaction (grade 2 or greater) to prior paclitaxel or other therapy containing Cremophor EL
- allergy or intolerance to steroids, diphenhydramine, cimetidine, or ranitidine
- uncontrolled concurrent illness
- active infection
- pregnant or nursing
- other concurrent anticancer therapies or commercial agents
- other concurrent investigational agents
- other concurrent highly active antiretroviral therapy for HIV-positive patients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005807
United States, New York | |
Albert Einstein Clinical Cancer Center | |
Bronx, New York, United States, 10461 | |
NYU School of Medicine's Kaplan Comprehensive Cancer Center | |
New York, New York, United States, 10016 |
Study Chair: | Franco M. Muggia, MD | NYU Langone Health | |
Principal Investigator: | Sridhar Mani, MD | Albert Einstein College of Medicine |
Responsible Party: | Albert Einstein College of Medicine |
ClinicalTrials.gov Identifier: | NCT00005807 |
Other Study ID Numbers: |
CDR0000067800 AECM-9911378 NCI-98 NYU-0006 |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | October 9, 2018 |
Last Verified: | October 2018 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
stage IV breast cancer stage IIIA breast cancer recurrent breast cancer stage IIIB breast cancer stage III ovarian epithelial cancer stage IV ovarian epithelial cancer recurrent ovarian epithelial cancer unspecified adult solid tumor, protocol specific |
ovarian stromal cancer stage III ovarian germ cell tumor stage IV ovarian germ cell tumor recurrent ovarian germ cell tumor borderline ovarian surface epithelial-stromal tumor ovarian sarcoma male breast cancer |
Breast Neoplasms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms |
Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Epothilones Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |